ALVR AlloVir, Inc.

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in 2013 and is headquartered in Houston, TX.

$4.13  +0.23 (5.90%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/30/2020
Outstanding shares:  65,417,547
Average volume:  384,716
Market cap:   $255,128,433
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BL9XBL4
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.32
PS ratio:   0.00
Return on equity:   -155.95%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy